Ono Pharmaceutical Co., Ltd. (TYO: 4528)
Japan
· Delayed Price · Currency is JPY | Market Cap | 754.35B |
| Revenue (ttm) | 484.30B |
| Net Income (ttm) | 95.13B |
| Shares Out | 469.71M |
| EPS (ttm) | 201.49 |
| PE Ratio | 7.97 |
| Forward PE | 11.51 |
| Dividend | 80.00 (4.98%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 4,049,300 |
| Open | 1,630.00 |
| Previous Close | 1,608.00 |
| Day's Range | 1,600.50 - 1,631.00 |
| 52-Week Range | 1,600.50 - 2,777.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 3, 2025 |
About Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv t... [Read more]
Financial Performance
In 2023, Ono Pharmaceutical's revenue was 502.67 billion, an increase of 12.41% compared to the previous year's 447.19 billion. Earnings were 127.98 billion, an increase of 13.53%.
Financial StatementsNews
Ono Pharmaceutical reports Q2 results
Equillium says Ono not acquiring itolizumab, stock craters 36%
Equillium (EQ) stock cratered 36% after the company said it was pausing certain programs due to Ono Pharmaceutical failing to exercise an option to acquire its drug itolizumab.
Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical
Kinaxis provides end-to-end supply chain orchestration platform to support Ono Pharmaceutical’s further global growth OTTAWA, Ontario — Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply ch...
Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical
OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Ono Pharmaceutical Co., Ltd.'s adoption of Kinaxis to help orchestr...
Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical
LONDON & BUDAPEST, Hungary--(BUSINESS WIRE)--Turbine, the biological simulation company using AI to build a digital lab for predictive computational models of human cells and tissue, today announced t...
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript
Ono Pharmaceutical Co., Ltd. (OTCPK:OPHLF) Q1 2024 Earnings Conference Call May 9, 2024 8:30 PM ET Company Participants Gyo Sagara - Representative, Director, Chairman of the Board and CEO Tatsuya Oka...
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
OSAKA, Japan , April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Ph...
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Deciphera Pharmaceuticals stock valued at $...
Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion
Deciphera Pharmaceuticals Inc. DCPH, +3.31% said Monday it has agreed to be acquired by Japan's Ono Pharmaceutical Co. Ltd 4528, +1.34% in an all-cash deal valued at $2.4 billion. Under the terms of t...
Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion
Deciphera Pharmaceuticals said on Monday Japan's ONO Pharmaceutical Co will acquire the company for $2.4 billion in cash.
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
NM49 is a multi-specific antibody identified through Numab's proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis
Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets
LONDON, & BUDAPEST, Hungary--(BUSINESS WIRE)--Turbine, a computational biology company that deploys empirically validated in silico cell simulations to guide biopharma R&D, today announced that it has...